EASL Roundup: Bristol-Myers and NGM post a positive look at PhII NASH data; Genfit details PhIII delay
Over the weekend some of the prospective players in the NASH field had a chance to roll out new data on their contenders for the field at the annual EASL meeting. We were treated to some intriguing early- and mid-stage data on liver fat levels that could be important further down the R&D road. And a top late-stage player spotlighted a delay that could set it behind rivals in the field.
Bill Berkrot at Reuters did a great deep dive on NASH, a big market disease that could be worth tens of billions of dollars every year. NASH and fatty liver disease are the hallmark of an increasingly obese, sedentary global population. Ultimately, the disease could lead to liver transplants, though there is a lot left to be learned about disease progression and risk.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.